Formulations and carrier systems including compound interactive domains

Abstract

A method of creating a formulation for a compound includes determining a compound interactive agent comprising at least one group that interacts with the compound, creating a carrier agent by conjugating at least one compound interactive domain comprising the at least one group that interacts with the compound with at least one hydrophilic domain, and combining the compound and the carrier agent to create the formulation. Creating the carrier agent may further include conjugating the at least one compound interactive domain with at least one hydrophobic domain so that the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain.

What is claimed is: 
     
         1 . A method of creating a formulation for a compound, comprising:
 determining a compound interactive agent comprising at least one group that interacts with the compound via hydrogen bonding, via charge interaction or via π-π interaction,   creating a carrier agent by conjugating at least one compound interactive domain comprising the at least one group that interacts with the compound with at least one hydrophilic domain and with at least one hydrophobic domain so that the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain, the compound interactive domain being different from the at least one hydrophilic domain and from the at least one hydrophobic domain, and   combining the compound and the carrier agent to create the formulation.   
     
     
         2 . The method of  claim 1  wherein the at least one hydrophobic domain comprises a lipid. 
     
     
         3 . The method of  claim 1  wherein the at least one hydrophilic domain comprises at least one hydrophilic oligomer or at least one hydrophilic polymer. 
     
     
         4 . The method of  claim 3  wherein the hydrophilic oligomer or the hydrophilic polymer is a polyalkylene oxide, a polyvinylalcohol, a polyacrylic acid, a polyacrylamide, a polyoxazoline, or a polypeptide. 
     
     
         5 . The method of  claim 1  wherein the at least one hydrophilic domain comprises at least one ionic group, at least one carboxylic acid group, at least one amine group, at least one saccharide group, or at least one polysaccharide group. 
     
     
         6 . The method of  claim 1  wherein the compound interactive domain comprises at least one amino acid group or at least one peptide group. 
     
     
         7 . The method of  claim 1  wherein the compound interactive domain comprises at least one of a fluorenylmethyloxycarbonyl group, a carbobenzyloxy group, an isobutoxycarbamate group, a naphthylacetyl group, a carbazole group, a quinolone group, an isoquinolone group, or a group which is a residue of a molecule selected from the group of the compound, a portion of the compound, (9H-fluoren-9-yl)methanamine, (9H-fluoren-9-yl)methanol, 9H-fluoren-9-amine, naphthalene, 1,1′-bi-2-naphthol (BINOL), camptothecin, a camptothecin analog, pemetrexed, docetaxel, paclitaxel, epirubicin, doxorubicin, vinblastine, vindesine, etoposide, hydroxycamptothecin, irinotecan, mitoxantrone, tamoxifen, tretinoin, Vitamin A, Vitamin E, Vitamin K, Vitamin D, curcumin, imatinib, gefitinib, erlotinib, sorafenib, and bortezomib, or a derivative thereof. 
     
     
         8 . The method of  claim 1  wherein the compound interactive domain comprises at least one fluorenylmethyloxycarbonyl group or a derivative thereof. 
     
     
         9 . The method of  claim 7  wherein the formulation forms a complex selected from a group consisting of a micelle, an emulsion, a cream, a liposome, a spherulite, a solid-lipid nanoparticle, a hydrogel or a cubic phase lipogel. 
     
     
         10 . The method of  claim 1  wherein the at least one hydrophobic domain comprises at least one lipid, at least one tocopherol, at least one hydrophobic oligomer or at least one hydrophobic polymer. 
     
     
         11 . The method of  claim 1  wherein the at least one hydrophobic domain comprises at least one of a polymethylacryl, a polyethylene, a polystyrene, a polyisobutane, a polyester, a polypeptide, or a derivative thereof. 
     
     
         12 . The method of  claim 1  wherein the at least one hydropobic domain comprises a farnesylthiosalicylate group. 
     
     
         13 . The method of  claim 1  wherein the compound is JP4-039, paclitaxel, FK506, cyclosporin A, a protoporphyrin, GW4064, rose bengal, epigallocatechin gallate, curcumin, indomethacin, tamoxifen or doxorubicin. 
     
     
         14 . The method of  claim 1  wherein the compound is paclitaxel, the hydrophilic domain comprises polyethylene glycol and the interactive domain comprises at least one fluorenylmethyloxycarbonyl group or a derivative thereof. 
     
     
         15 . The method of  claim 1  wherein the at least one compound interactive domain of the carrier is covalently bonded to the at least one hydrophilic domain. 
     
     
         16 . The method of  claim 1  wherein the at least one compound interactive domain of carrier agent is covalently bonded to the at least one hydrophilic domain and is covalently bonded to the at least one hydrophobic domain. 
     
     
         17 . A formulation to deliver a compound to a patient, comprising:
 the compound and a carrier agent comprising at least one hydrophilic domain conjugated with at least one compound interactive domain comprising at least one group that interacts with the compound and at least one hydrophobic domain conjugated with the at least one interactive domain which interacts with the compound via hydrogen bonding, via charge interaction or via π-π interaction, wherein the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain.   
     
     
         18 . The formulation of  claim 17  wherein the at least one hydrophobic domain comprises at least one lipid, at least one tocopherol, at least one hydrophobic oligomer or at least one hydrophobic polymer. 
     
     
         19 . A method of creating a formulation to deliver a compound to a patient, comprising:
 providing a carrier agent comprising at least one hydrophilic domain conjugated with at least one compound interactive domain comprising at least one group that interacts with the compound and at least one hydrophobic domain conjugated with the at least one interactive domain, wherein the at least one compound interactive domain is positioned between the at least one hydrophilic domain and the at least one hydrophobic domain, the compound interactive domain being different from the at least one hydrophilic domain and from the at least one hydrophobic domain and interacting with the compound via hydrogen bonding, via charge interaction or via π-π interaction; and   combining the compound and the carrier agent.   
     
     
         20 . The method of  claim 19  wherein the at least one hydrophobic domain comprises at least one lipid, at least one tocopherol, at least one hydrophobic oligomer or at least one hydrophobic polymer.